Granisetron Fresenius Kabi

Granisetron Fresenius Kabi is an intravenous formulation containing the active ingredient granisetron hydrochloride. It is a prescription‑only 5‑HT3 receptor antagonist marketed in the European Union. The product is used to prevent nausea and vomiting associated with chemotherapy and surgery, acting by selectively blocking serotonin receptors in the central nervous system.

Granisetron Fresenius Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings. It is commonly employed in oncology and peri‑operative care.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) - Prevention of postoperative nausea and vomiting (PONV) - Use as part of anti‑emetic prophylaxis protocols - Administration before highly emetogenic chemotherapy regimens - Use in patients at high risk for nausea and vomiting due to surgical procedures

Granisetron Fresenius Kabi may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.

Common: - Headache - Constipation - Fatigue - Dizziness - Injection site discomfort

Serious: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmias or QT prolongation

When prescribing Granisetron Fresenius Kabi, clinicians should consider several safety aspects to minimize risk.

- Assess patient history for cardiac disease or electrolyte abnormalities - Use caution in patients with prolonged QT interval - Monitor for signs of hypersensitivity during and after infusion - Adjust dose in patients with hepatic impairment as recommended - Avoid use in patients with known hypersensitivity to granisetron or related compounds - Evaluate pregnancy and lactation status; safety data are limited

Granisetron Fresenius Kabi can interact with other medications, influencing its efficacy or safety profile.

Avoid: - Other 5‑HT3 antagonists used concurrently - Drugs known to significantly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics)

Use with caution: - CYP3A4 inhibitors or inducers that may affect granisetron metabolism - Anticholinergic agents that could exacerbate constipation - Opioids, as they may increase the risk of constipation - Medications that also affect cardiac conduction